Trial Seeks Participants to Study AVB-500 Plus Imfinzi in Platinum-resistant Ovarian Cancers

Trial Seeks Participants to Study AVB-500 Plus Imfinzi in Platinum-resistant Ovarian Cancers
Aravive is recruiting participants for a Phase 1/2 clinical trial assessing a combination of its experimental treatment AVB-500 plus the immune checkpoint inhibitor Imfinzi (durvalumab) in women with platinum-resistant epithelial ovarian cancer. The trial (NCT04019288) is ongoing at the MD Anderson Cancer Center, in Texas, and is expected to include 36 participants with high grade epithelial ovarian, peritoneal, or fallopian tube cancer who have no standard-of-care treatment options available. AVB-500 is a fusion protein that binds with high affinity to the GAS6 protein, and works as a decoy that significantly reduces or prevents GAS6’s ability to bind and stimulate the AXL receptor pathway — which plays a key role in cancer progression. High levels of GAS6 in the blood are associated with more aggressive cancer, resistance to treatment, and poorer outcomes in people with ovarian and breast cancer. “We believe there is a strong mechanistic and clinical rationale for exploring the potential of AVB-500 in combination with a checkpoint inhibitor in the treatment of ovarian cancer,” Gail McIntyre, PhD, chief scientific officer of Aravive, said in a
Subscribe or to access all post and page content.